Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA 'to promote' Stefan Oschmann to chief executive

Germanphamra company reportedly set to elevate him to the top job next year

Merck KGaA Stefan OschmannMerck KGaA is set to elevate its deputy chief executive Stefan Oschmann to replace chief executive Karl-Ludwig Kley, according to local reports.

Manager Magazin says the German pharma company plans to promote Oschmann next year, either after its annual general meeting in May 2016 or when Kley's contract expires in September.

But a Merck spokeswoman told Reuters that a decision on Kley's succession had not yet been made and that this would be a matter for the family-controlled group's board of partners.

Oschmann has been vice chairman of Merck's executive board since January and prior to this was responsible for Merck's Pharma business as Member of the Executive Board from 2011 to 2014.

Before joining Germany's Merck he worked for its namesake Merck & Co as the US company's president of emerging markets for Merck Sharp & Dohme (MSD), as its operations are known outside the US.

Prior to joining MSD Oschmann worked for the International Atomic Energy Agency IAEA from 1985 to 1987 and for the German Animal Health Federation (BfT) from 1987 to 1989.

26th March 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics